Logo image of TSBX

TURNSTONE BIOLOGICS CORP (TSBX) Stock Price, Quote, News and Overview

NASDAQ:TSBX - Nasdaq - US90042W1009 - Common Stock - Currency: USD

0.3629  0 (-0.82%)

Premarket: 0.3764 +0.01 (+3.72%)

TSBX Quote, Performance and Key Statistics

TURNSTONE BIOLOGICS CORP

NASDAQ:TSBX (6/10/2025, 8:13:07 PM)

Premarket: 0.3764 +0.01 (+3.72%)

0.3629

0 (-0.82%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.05
52 Week Low0.29
Market Cap8.40M
Shares23.14M
Float18.26M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO07-21 2023-07-21


TSBX short term performance overview.The bars show the price performance of TSBX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20

TSBX long term performance overview.The bars show the price performance of TSBX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of TSBX is 0.3629 USD. In the past month the price increased by 8.62%. In the past year, price decreased by -86.56%.

TURNSTONE BIOLOGICS CORP / TSBX Daily stock chart

TSBX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.45 334.73B
AMGN AMGEN INC 14.13 157.78B
GILD GILEAD SCIENCES INC 14.22 136.94B
VRTX VERTEX PHARMACEUTICALS INC N/A 115.95B
REGN REGENERON PHARMACEUTICALS 11.82 56.53B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.44B
ARGX ARGENX SE - ADR 100.08 35.14B
ONC BEONE MEDICINES LTD-ADR 6.74 28.50B
BNTX BIONTECH SE-ADR N/A 25.70B
NTRA NATERA INC N/A 22.56B
BIIB BIOGEN INC 8.56 19.85B
INSM INSMED INC N/A 16.56B

About TSBX

Company Profile

TSBX logo image Turnstone Biologics Corp. operates as a clinical stage biotechnology company. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2023-07-21. The firm is focused on developing new medicines to treat and cure patients with solid tumors. The company is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. The company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. The company is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.

Company Info

TURNSTONE BIOLOGICS CORP

9310 Athena Circle, Suite 300

La Jolla CALIFORNIA US

Employees: 82

TSBX Company Website

TSBX Investor Relations

Phone: 13478975988

TURNSTONE BIOLOGICS CORP / TSBX FAQ

What is the stock price of TURNSTONE BIOLOGICS CORP today?

The current stock price of TSBX is 0.3629 USD. The price decreased by -0.82% in the last trading session.


What is the ticker symbol for TURNSTONE BIOLOGICS CORP stock?

The exchange symbol of TURNSTONE BIOLOGICS CORP is TSBX and it is listed on the Nasdaq exchange.


On which exchange is TSBX stock listed?

TSBX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TURNSTONE BIOLOGICS CORP stock?

6 analysts have analysed TSBX and the average price target is 1.02 USD. This implies a price increase of 181.07% is expected in the next year compared to the current price of 0.3629. Check the TURNSTONE BIOLOGICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TURNSTONE BIOLOGICS CORP worth?

TURNSTONE BIOLOGICS CORP (TSBX) has a market capitalization of 8.40M USD. This makes TSBX a Nano Cap stock.


How many employees does TURNSTONE BIOLOGICS CORP have?

TURNSTONE BIOLOGICS CORP (TSBX) currently has 82 employees.


What are the support and resistance levels for TURNSTONE BIOLOGICS CORP (TSBX) stock?

TURNSTONE BIOLOGICS CORP (TSBX) has a support level at 0.32 and a resistance level at 0.37. Check the full technical report for a detailed analysis of TSBX support and resistance levels.


Should I buy TURNSTONE BIOLOGICS CORP (TSBX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TURNSTONE BIOLOGICS CORP (TSBX) stock pay dividends?

TSBX does not pay a dividend.


What is the Price/Earnings (PE) ratio of TURNSTONE BIOLOGICS CORP (TSBX)?

TURNSTONE BIOLOGICS CORP (TSBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.73).


What is the Short Interest ratio of TURNSTONE BIOLOGICS CORP (TSBX) stock?

The outstanding short interest for TURNSTONE BIOLOGICS CORP (TSBX) is 1.68% of its float. Check the ownership tab for more information on the TSBX short interest.


TSBX Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to TSBX. When comparing the yearly performance of all stocks, TSBX is a bad performer in the overall market: 95.36% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

TSBX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TSBX. While TSBX seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TSBX Financial Highlights

Over the last trailing twelve months TSBX reported a non-GAAP Earnings per Share(EPS) of -2.73. The EPS increased by 73.08% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -228.2%
ROE -315.29%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%40%
Sales Q2Q%N/A
EPS 1Y (TTM)73.08%
Revenue 1Y (TTM)-100%

TSBX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to TSBX. The Buy consensus is the average rating of analysts ratings from 6 analysts.


Ownership
Inst Owners45.33%
Ins Owners3.83%
Short Float %1.68%
Short Ratio3.59
Analysts
Analysts43.33
Price Target1.02 (181.07%)
EPS Next Y77.07%
Revenue Next YearN/A